<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003551</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066608</org_study_id>
    <secondary_id>EUSM-HIC-748-96</secondary_id>
    <secondary_id>NCI-T96-0110</secondary_id>
    <nct_id>NCT00003551</nct_id>
  </id_info>
  <brief_title>Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer</brief_title>
  <official_title>A Phase II Study of 9-Amino-20(S)-Camptothecin (9-AC) (NSC 603071) and Evaluation of Drug Resistance in Patients With Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients&#xD;
      with stage III, stage IV, or recurrent kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the response rate, duration of response, and survival of patients&#xD;
      with advanced renal cell carcinoma treated with aminocamptothecin colloidal dispersion. II.&#xD;
      Determine the nature and degree of toxicity of aminocamptothecin in this patient population.&#xD;
&#xD;
      OUTLINE: Patients receive aminocamptothecin colloidal dispersion intravenously for 120 hours&#xD;
      weekly for 2 weeks followed by 1 week of rest. Courses are repeated every 3 weeks in the&#xD;
      absence of disease progression or dose limiting toxicity. Patients are followed every 3&#xD;
      months for the first 2 years, every 6 months for the next 3 years, and yearly thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1998</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aminocamptothecin colloidal dispersion</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven stage III, stage IV, or recurrent renal cell&#xD;
        carcinoma Measurable disease No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At&#xD;
        least 3 months Hematopoietic: Platelet count at least 100,000/mm3 Absolute neutrophil count&#xD;
        at least 1500/mm3 Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin no greater than 1.5 mg/dL&#xD;
        ALT and AST no greater than 2.5 times the institutional normal values Renal: Creatinine no&#xD;
        greater than 1.5 mg/dL Other: Not pregnant or nursing Fertile patients must use effective&#xD;
        contraception No uncontrolled systemic infection No other prior or concurrent malignancies&#xD;
        except nonmelanoma skin cancer, carcinoma in situ of the cervix, or ductal carcinoma in&#xD;
        situ of the breast that have been curatively treated No evidence of delirium, confusion,&#xD;
        suicidal ideation, or untreated depression&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 30 days since prior cytokines and&#xD;
        recovered No more than 1 prior treatment with cytokines (interleukin-2 or interferons)&#xD;
        Chemotherapy: No prior cytotoxic chemotherapy No prior aminocamptothecin No other&#xD;
        concurrent antineoplastic agents Endocrine therapy: At least 30 days since prior hormone&#xD;
        therapy and recovered No more than 1 prior hormone therapy (tamoxifen or&#xD;
        medroxyprogesterone) Radiotherapy: Prior radiotherapy allowed if indicator lesion and&#xD;
        greater than 15% of marrow producing bone have not been irradiated Surgery: Recovered from&#xD;
        prior surgery Other: At least 30 days since other investigational agents No concurrent&#xD;
        investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Keane, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2000</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2004</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

